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Introduction.We previously showed that in HNF1A-MODY the cystatin C-based glomerular filtration rate (GFR) estimate is higher
than the creatinine-based estimate. Currently, we aimed to replicate this finding and verify its clinical significance. Methods. The
study included 72 patients with HNF1A-MODY, 72 with GCK-MODY, 53 with type 1 diabetes (T1DM), 70 with type 2 diabetes
(T2DM), and 65 controls. Serum creatinine and cystatin C levels were measured. GFR was calculated from creatinine and cystatin
C using the CKD-EPI creatinine equation (eGRF-cr) and CKD-EPI cystatin C equation (eGFR-cys), respectively. Results. Cystatin
C levels were lower (𝑝 < 0.001) in the control (0.70 ± 0.13mg/L), HNF1A (0.75 ± 0.21), and GCK (0.72 ± 0.16mg/L) groups
in comparison to those with either T1DM (0.87 ± 0.15mg/L) or T2DM (0.9 ± 0.23mg/L). Moreover, eGFR-cys was higher
than eGRF-cr in HNF1A-MODY, GCK-MODY, and the controls (𝑝 = 0.004; 𝑝 = 0.003; 𝑝 < 0.0001). This corresponded to
8.9mL/min/1.73m2, 9.7mL/min/1.73m2, and 16.9mL/min/1.73m2 of difference. Additionally, T1DM patients had higher eGFR-
cr than eGFR-cys (11.6mL/min/1.73m2; 𝑝 = 0.0004); no difference occurred in T2DM (𝑝 = 0.91). Conclusions. We confirmed
that eGFR-cys values in HNF1A-MODY patients are higher compared to eGFR-cr. Some other differences were also described in
diabetic groups. However, none of them appears to be clinically relevant.
1. Introduction
Diabetic kidney disease (DKD) is the leading cause of end-
stage renal disease (ESRD) and is associatedwith an increased
risk of cardiovascular mortality [1, 2]. In spite of substantial
progress in treatment and monitoring methods, the risk
of ESRD remains high in both type 1 (T1DM) and type
2 diabetes (T2DM) [3, 4]. Monitoring of DKD occurrence
and progression is considered crucial for prevention of
kidney damage. Over recent decades, clinical guidelines
recommended measuring albumin excretion rate in order
to monitor progress of DKD [5]. However, recent scientific
data suggest that the loss of glomerular filtration rate (GFR),
rather than albuminuria, should be the main outcome in
diabetic kidney research and clinical practice [6]. In everyday
manner, GFR is measured using one of two estimates. The
first is based on serum creatinine level while the second
estimate is built on serum cystatin C level [7, 8].The Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI) has
provided a formula for each estimation. Cystatin C is a 13-
kDa cysteine proteinase inhibitor and is produced by all
nucleated cells at a constant rate. In healthy subjects, cystatin
C is freely filtered by the renal glomeruli and almost entirely
reabsorbed in the proximal tubule like other low molecular
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weight proteins [9].The cystatin C GFR estimate has recently
been recommended with increasing frequency as having
important advantages over its alternatives [8].
We previously postulated that cystatin C level might also
be a biomarker for HNF1A-MODY, a monogenic form of
diabetes, as concomitant kidney phenotypes were described
in this form of disease [10]. Our hypothesis was excluded
by examining three different HNF1A-MODY cohorts, one
from Poland and two from the UK. Interestingly, in all
examined HNF1A-MODY groups, we consistently observed
that the cystatin C-based GFR (2008 equation) estimate
was higher than the creatinine-based one. The difference
between the estimates reached 25mL/min/1.73m2 in one
cohort. Such a difference may be of clinical importance
and lead to inappropriate clinical decisions. This previous
finding required further confirmation. Moreover, since then,
a new equation has been recommended for cystatin C eGFR
calculation [8].
In the current study, we aimed to replicate our previous
finding that in HNF1A-MODY patients estimation of GFR
from serum cystatin C is higher than from serum creatinine
and to verify whether this difference is clinically relevant.
2. Material and Methods
The study included 72 patients with HNF1A-MODY, 72 with
GCK-MODY, 53 with T1DM, and 70 with T2DM as well as
65 control subjects. All patients received the medical care at
the Department of Metabolic Diseases, University Hospital
in Krakow, a tertiary referral center for diabetes care in
southeastern Poland.
The individuals were considered as diagnosed with dia-
betes if at the study entry they were on hypoglycemic
treatment or met the diagnostic criteria based on fasting
glucose level measurements. The subjects were white Cau-
casians, the residents of southeastern Poland. All examined
MODYpatients had amolecular diagnosis established during
research activities performed at the Jagiellonian University
Medical College [11, 12]. The pathogenicity of mutations
was determined based on earlier reports, DNA sequence
difference molecular character, and segregation within the
families. Subjects with T1DM were identified if at diagno-
sis they had typical clinical symptoms, an insulin therapy
requirement from the beginning of the disease, and dia-
betes diagnosed below 30 years of age. We also included
patients with a clinical diagnosis of T2DM who at least 2
years after diagnosis remained without insulin therapy. The
control group consisted of apparently healthy subjects with
normal fasting glucose levels. No individual with known
thyroid gland function abnormality or on steroid therapy
was included into this study. Subjects received a standard
questionnaire and underwent a basic physical examination.
For all study individuals, we collected data on their clinical
characteristics. None of the individuals from the GCK-
MODY, T2DM, T1DM, and control group was evaluated in
our previous report. Twenty-two patients from the HNF1A-
MODY group were previously included; however, they were
currently invited for a new examination and sample draw.
We excluded all individualswith active infections, neoplasms,
severe chronic diseases of the respiratory tract, kidney, or
liver as well as pregnant women. This study was performed
according to the Helsinki Declaration and it was approved by
the Bioethical Committee of the Jagiellonian University.
We performed clinical laboratory analyses, such asHbA1c
level, fasting glucose, lipids, CRP, creatinine level, and the
urinary albumin-to-creatinine ratio (ACR). The previously
described methods were used [11, 12]. Serum cystatin C was
measured using an immunoturbidimetric method (APTEC
Diagnostics nv, Belgium) on the Maxmat PLII clinical chem-
istry analyzer (Maxmat S. A., Montpellier, France) calibrated
against the international certified reference material ERM-
DA471/IFCC. EstimatedGFRwas calculated from serum cre-
atinine and cystatinC level using theCKD-EPI formula [7, 8].
Statistical analysis was performed to determine the differ-
ence between two (𝑡-student) and several groups (ANOVA
with post hoc tests). If necessary, nonparametric tests were
utilized as equivalents. Predictive multivariate linear regres-
sion analysis was used to assess if differences between both
eGFRs (counted from cystatin C and creatinine) changed
in diagnosis groups after adjustment for gender, age, BMI,
glucose level, CRP concentration, HDL level, and total
cholesterol level. Statistical analyses were performed using
STATISTICA ver. 10.0 and R ver. 3.1.1 software.
3. Results
The study groups’ characteristics are shown in Table 1. Dis-
tribution variations among diabetic groups for age, BMI, and
diabetes duration were in line with the way the groups were
defined. We identified 8 patients with chronic kidney disease
(CKD) defined as CKD-EPI creatinine equation (eGRF-cr)
<60mL/min/1.73m2; there were 5 such individuals in the
T2DM group, 2 in HNF1A-MODY group, and 1 in T1DM
group.
Differences in cystatin C level were identified between
study groups (𝑝 < 0.001). In the post hoc analysis (Tukey test)
cystatin C levels were significantly lower (𝑝 < 0.0016) in the
control (0.70±0.13mg/L),HNF1A-MODY (0.75±0.21mg/L),
and GCK-MODY (0.2 ± 0.16mg/L) groups in comparison to
those with either T1DM (0.87 ± 0.15mg/L) or T2DM (0.9 ±
0.23mg/L).
We observed that eGFR-cys was higher than eGRF-cr
in three groups: HNF1A-MODY, GCK-MODY, and controls
(𝑝 = 0.004; 𝑝 = 0.003; 𝑝 < 0.0001) as shown in Table 1. This
corresponded to rates of 8.9, 9.7, and 16.9mL/min/1.73m2,
respectively. Contrarily, in T1DM patients, eGFR-cr was
higher than eGFR-cys (11.6mL/min/1.73m2; 𝑝 = 0.0004). No
significant difference between both estimates was observed in
T2DM (𝑝 = 0.91).
We further analyzed if differences between both GFRs
remained significant in the multivariate regression model.
It was revealed that differences between the GFR estimates
within groups remained almost unchanged and, thus, unre-
lated to main clinical features.
Additionally, we determined the median eGFR-cr in
every group. The range of the medians varied between
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Table 1: Clinical characteristics of patients and controls without diabetes.
Clinical characteristics HNF1A GCK T1DM T2DM Controls 𝑃 value∗
Gender F𝑁 (%) 26 (36.1) 29 (40.3) 21 (55.7) 39 (55.7) 23 (35.4) 0.0990
Age at the examination (years) 40.28 ± 14.77 36.83 ± 14.65 31.72 ± 11.71 58.96 ± 10.25 38.02 ± 11.70 <0.0001
Age at diagnosis (years) 24.95 ± 10.96 26.19 ± 13.09 18.58 ± 10.97 52.16 ± 10.34 — <0.0001
Diabetes duration (years) 16.7 ± 11.02 10.58 ± 8.15 12.81 ± 9.45 6.8 ± 6.41 — <0.0001
Body mass index (kg/m2) 24.05 ± 4.00 23.64 ± 4.40 24.43 ± 3.20 30.48 ± 4.76 23.91 ± 2.93 <0.0001
Fasting glucose (mmol/L) 6.91 ± 2.68 6.82 ± 1.21 7.92 ± 3.18 7.52 ± 1.94 5.12 ± 0.53 <0.0001
HbA1c (%) 6.83 ± 1.41 6.33 ± 0.67 7.41 ± 1.30 7.04 ± 1.33 — <0.0001
C-peptide (ng/mL) 1.33 ± 0.66 1.31 ± 0.98 0.20 ± 0.25 2.41 ± 1.23 1.55 ± 0.66 <0.0001
Total cholesterol (mmol/L) 4.79 ± 0.97 5.05 ± 1.09 4.41 ± 0.76 4.61 ± 0.97 5.04 ± 0.81 0.0005
LDL-C (mmol/L) 2.64 ± 0.86 2.97 ± 0.85 2.44 ± 0.72 2.56 ± 0.84 3.04 ± 0.76 <0.0001
HDL-C (mmol/L) 1.59 ± 0.42 1.62 ± 0.42 1.63 ± 0.43 1.23 ± 0.37 1.53 ± 0.41 <0.0001
Triglycerides (mmol/L) 1.23 ± 0.92 0.93 ± 0.36 0.85 ± 0.36 1.82 ± 1.02 1.01 ± 0.49 <0.0001
Creatinine (mmol/L) 70.39 ± 15.26 70.46 ± 14.33 68.63 ± 14.77 75.34 ± 17.61 74.4 ± 13.12 0.0646
CRP (mg/L) 0.71 ± 1.16 1.69 ± 2.85 1.53 ± 1.47 3.2 ± 5.06 0.95 ± 0.89 <0.0001
Cystatin C (mg/L) 0.75 ± 0.21 0.72 ± 0.16 0.87 ± 0.15 0.9 ± 0.23 0.70 ± 0.13 <0.0001
Urine albumin/creatine ratio (𝜇g/mg) 6.38 ± 29.62 2.72 ± 13.06 3.66 ± 9.27 7.38 ± 17.85 — 0.0439
eGFR-cys (mL/min/1.73m2) 110.94 ± 21.57 113.73 ± 18.49 100.02 ± 17.55 89.64 ± 21.64 116.24 ± 15.56 <0.0001
eGFR-cr (mL/min/1.73m2) 102.86 ± 19.32 105.14 ± 18.13 111.48 ± 15.8 88.66 ± 16.99 99.45 ± 14.35 <0.0001
eGRF-cys - eGFR-cr (ml/min/1.73m2) −8.9 ± 18.7 −9.7 ± 17.0 11.6 ± 21.2 −1.00 ± 16.3 −16.9 ± 15.0 <0.0001
Data are presented as mean and standard deviation (SD). For categorical variable numbers and percentage were used.
∗
𝑃 value derived from one-way analysis of variance (ANOVA) or Kruskal-Wallis test to detect a significant difference in the variable levels among study groups.
115mL/min/1.73m2 in T1DM and 92mL/min/1.73m2 in
T2DM.We then calculated differences between eGFR-cr and
GFR-cys in subgroups below and above the eGFR-cr median
in every diagnosis group. For the “above median” analysis,
the range of eGFR-cr and GFR-cys differences varied from
18.2mL/min/1.73m2 in T1DM to −0.5mL/min/1.73m2 in
T2DM. In the HNF1A-MODY group it reached −2.4 ± 19.0
(𝑝 = 0.22), whereas, for the “below median” comparisons,
the differences ranged from −1.5mL/min/1.73m2 in T2DM
up to −22.1mL/min/1.73m2 in the controls. In the HNF1A-
MODY, GFR-cys was higher than GFR-cr by −14.6 ± 16.6
(𝑝 < 0.0001).
We also performed all analyses after excluding 22
HNF1A-MODYpatients whose earlier specimenswere exam-
ined in our previous report. This exclusion did not substan-
tially change the study results (data not shown).
4. Discussion
In this study, we confirmed that eGFR-cys was higher than
eGRF-cr in HNF1A-MODY. Moreover, this difference was
found to be unrelated to the main clinical features of the
examined patients. This is in line with our previous results
from three cohorts: one from Poland and two from the UK
[10]. Nevertheless, the magnitude of the difference between
both estimates does not appear to have a clinical significance.
Impaired GFR is, together with increased albumin excre-
tion rate, a sign of diabetic kidney damage. GFR is in clin-
ical practice estimated, rather than measured, using serum
creatinine level as the most common approach. However,
the creatinine level is influenced by a number of clinical
factors, such as age, muscle mass, sex, and race [13]. Given
these limitations, serum cystatin C has been proposed as an
alternative GFR marker [9]. Cystatin C is less affected by
features influencing creatinine level; moreover, in the general
population it associates more strongly with all cause and
cardiovascular mortality than does serum creatinine [14].
A significant association was found between cardiovascular
mortality and low eGFRcys, but not eGFRcr, among diabetic
patients from the largeUSNHANES registry [15].The clinical
utility of cystatin-based eGFR was also demonstrated in
another clinical study in which only the cystatin C-based
chronic kidney disease definition was an independent risk
predictor for cardiovascular events [16]. However, factors
such as BMI, diabetes, and inflammationmay impact cystatin
C levels to some degree independently of kidney function
[9]. In general, results obtained for eGFR-cr highly corre-
late with those calculated from eGFR-cys [17]. However, it
was suggested that, in persons with diabetes, cystatin C-
based estimate use would result in a higher prevalence of
reduced renal function than would estimate based on serum
creatinine [15]. Moreover, reclassification from preserved
kidney function defined based on creatinine level to reduced
kidney function using cystatin C occurredmore often among
persons with diabetes than among those without [15].
There were some earlier reports comparing both esti-
mates in common forms of diabetes. It was shown that in
T1DM GFR estimated from cystatin C reflects normal and
elevated renal function better than its creatinine alternative
even during hyperglycemia [18]. It was also suggested that
the addition of cystatin C to creatinine to estimate GFR may
improve identification of the causes and consequences of
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GFR loss in T1DM [19]. On the other hand, a comparison of
GFR estimated from creatinine and cystatin Cwithmeasured
GFR in a large group of participants consisting exclusively
of T2DM with a broad range of renal function showed
no evidence of cystatin C-based approach superiority [20].
However, in T2DM patients with poor glycemic control, the
eGFR-cys was shown to be less biased andmore accurate than
the creatinine-based formula [21]. So far, to our knowledge,
there has been no study evaluating cys-GFR in any rare type
of diabetes, apart from our earlier report [10]. Interestingly,
the T1DM group in the current study was the only one with
a higher eGFR-cr than eGFR-cys. A satisfactorily compre-
hensive interpretation for this observation is not available
and replication of this finding is necessary. A possible
explanation could point to differences in glycemic control
between different diabetes types in our study. Of note, it was
earlier shown that eGFR-cr tends to overestimate glomerular
filtration as assessed by the reference inulin method in T1DM
under euglycemic conditions. During hyperglycemic clamp,
however, creatinine-based calculations underestimated the
inulin-based assessed GFR [18]. The impact of glucose values
characterizing the current study T1DM cohort on eGFR-cr in
everyday setting is unknown.
A cause of detected differences in HNF1A-MODY is not
clear. One may hypothesize that they are related to some
abnormalities in cystatin C synthesis or kidney reabsorption.
For example, HNF1A directly regulates the expression of the
chloride-proton exchanger ClC-5, which is essential for the
endocytic activity of the proximal tubule cells and the tubular
clearance of proteins filtered in the glomeruli [22]. It was also
shown in an animal model that structural changes, such as
diffuse glomerular nodules, were present in pigs carrying a
dominant-negative P291fsinsC mutation of the HNF1A gene
[23].
Our results should be interpreted within the limitation of
the study. First, we did not have a reliable gold standard for
GFR assessment. Performing inulin or iothalamate clearance
tests implies invasive and tedious procedures that lied outside
of the current research. Moreover, our study groups were
small, and we should acknowledge that much larger cohorts
were examined in earlier studies for the control population,
T1DM and T2DM; the size of these groups limited statistical
power of the analysis. Additionally, our study groups differed
in terms of some clinical characteristics; these differences
were definition linked with the clinical picture of the exam-
ined forms of diabetes. Also, themajority of subjects included
in this research had an eGFR above 60mL/min/1.73m2,
whichmakes our conclusions inapplicable to advanced stages
of renal disease. Finally, we did not perform a direct assess-
ment of any tubular defect inHNF1A-MODY and other study
groups [24]; instead, our investigations were limited to its
putative indirect effect on serum cystatin C or creatinine
level. In spite of these shortcomings, taking into account
the replication character of our HNF1A-MODY finding, we
consider our main conclusion to be well justified.
In summary, we confirmed that GFR values estimated
from serum cystatin C levels in HNF1A-MODY patients
are higher compared to eGFR from creatinine. Some other
differences were also described in remaining diabetic groups.
However, none of them appears to be clinically relevant.
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